William Blair Reaffirms ‘Outperform’ Rating for QuidelOrtho Stock

🌥️Trending News

QUIDELORTHO ($NASDAQ:QDEL): QuidelOrtho Corp is an orthopedic and spine care services firm. Its services include spine surgery, joint replacements, as well as rehabilitation and physical therapy. Recently, investment bankers William Blair have reaffirmed their ‘Outperform’ rating for QuidelOrtho’s stock. This is a positive development as it indicates that the financial performance of the company is viewed favourably by the market.

QuidelOrtho has carved a niche in the orthopedic and spine care market, offering a wide variety of services to customers. With a strong focus on patient care, the company has been able to expand its customer base significantly over the years. The Outperform rating from William Blair is a testament to the company’s commitment to delivering high quality services and products.

Share Price

The stock opened at $64.1 and closed at $62.8, lower by 2.2% from the prior closing price of $64.3. It has been reported that QUIDELORTHO CORP has been actively investing in research and development to increase its market share and share price over the past several months. As a result, the company’s stock has been performing relatively well, despite the recent dip. The ‘Outperform’ rating reaffirmed by William Blair indicates that the company’s stock may potentially continue to experience growth in the future. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Quidelortho Corp. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Quidelortho Corp. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Quidelortho Corp. More…

Key Ratios Snapshot

Some of the financial key ratios for Quidelortho Corp are shown below. More…

Analysis

GoodWhale has conducted an analysis of QUIDELORTHO CORP‘s fundamentals and found that their Star Chart shows a high health score of 7/10. This indicates that QUIDELORTHO CORP is able to pay off debt and fund future operations. Our analysis also classifies them as a ‘rhino’, a type of company we conclude has achieved moderate revenue or earnings growth. Based on these results, we believe that investors interested in long-term growth may be interested in QUIDELORTHO CORP. It is strong in growth and profitability, but weak in asset and dividend. We think it may be a good investment for those looking for future growth potential and stability. More…

Peers

Quidel Corporation is a leading provider of diagnostic healthcare solutions serving both the professional and consumer markets. The company manufactures and sells a broad range of diagnostic products, including immunoassays, molecular diagnostics, and infectious disease tests. Quidel’s products are used in hospitals, physician offices, clinics, and commercial laboratories, as well as at-home for self-testing. Quidel has a strong portfolio of products and a long history of providing high-quality diagnostics.

However, the company faces competition from a number of other companies, including LifePoint Inc, Bloom Health Partners Inc, and Talis Biomedical Corp.

– LifePoint Inc ($OTCPK:LFPI)

LifePoint Inc is a company that provides healthcare services. It has a market cap of 10.21k as of 2022 and a Return on Equity of 8.83%. The company has a strong ROE, which indicates that it is efficient in using its assets to generate profits. The company is doing well financially and is expected to continue to grow in the future.

– Bloom Health Partners Inc ($OTCPK:BLMHF)

The company’s market cap is 2.86M as of 2022. The company’s ROE is 26.8%. The company’s main products and services are health insurance, health care, and benefits administration. Health insurance coverage is provided to individuals, families, and businesses through a variety of plans. Health care services are delivered through a network of providers. Benefits administration services are provided to employers and employees.

– Talis Biomedical Corp ($NASDAQ:TLIS)

Talis Biomedical Corp is a medical technology company that develops and commercializes products based on its proprietary technology Platform for the early detection of infectious diseases. The Platform is designed to provide rapid, sensitive, and accurate detection of a wide range of infectious diseases. Talis Biomedical’s products are based on its proprietary platform technology, which is designed to provide rapid, sensitive, and accurate detection of a wide range of infectious diseases. Talis Biomedical’s products are intended for use in a variety of settings, including hospital emergency departments, primary care offices, and home health settings. Talis Biomedical’s products are currently in development and have not been cleared for commercial sale by the U.S. Food and Drug Administration.

Summary

Investment analysts at William Blair recently reaffirmed their stock rating of Quidel Ortho Corp (QUIDEL) as a “Market Perform”. Quidel Ortho is a publicly traded medical diagnostics company that focuses on developing, manufacturing, and marketing rapid diagnostic tests. Analysts point out that Quidel has a strong portfolio of products and services, as well as a high-quality management team. Furthermore, the company has a strong financial position with solid cash flow and debt ratios.

Despite this, analysts believe that the current market price already reflects the company’s potential and that there is limited upside. As such, they recommend against buying at this time, instead suggesting investors wait for more upside potential before investing.